After securing the $14 billion acquisition of Boston's Karuna Therapeutics Inc. last year, Bill Meury has now locked in another big biotech deal. In his next chief executive gig after securing the ...

Novartis is especially well positioned to advance abelacimab's clinical development and bring this innovative product to healthcare providers and patients," Bill Meury, CEO at Anthos, said.

After all the activity, Business Insider caught up with Allergan's newly promoted Chief Commercial Officer Bill Meury and Herm Cukier, Senior Vice President of Women's Healthcare, to hear what's ...

Bill Meury, Anthos chief executive, said the drug had the potential to be an “important treatment option” for millions of patients at high risk of stroke. Meury was appointed in April last ...

and we could not have more conviction in the potential of this asset," said Bill Meury, Chief Executive Officer at Anthos. "With its deep roots in the cardiovascular space, Novartis is especially ...